CD34+ cell in cord blood and neonates

0Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

CD34 surface antigen has been extensively used as a marker for hematopoietic stem cells in adult bone marrow. Cord blood contains high number of hematopoietic and non-hematopoietic stem/progenitor cells. This chapter focuses on recent progresses in stem cell biology on cord blood cells. During embryonic development, expression of CD34 is tightly regulated in a spatial and temporal manner. Subpopulations of CD34+ cells in cord blood have been characterized by their functional potency. CD133 positivity and aldehyde dehydrogenase activity are well overlapped to show higher regenerative potentials in CD34+ cells. Proportion of CD34+ cells tends to be higher in cord blood from preterm baby. The higher number of circulating CD34+ cells in neonate has been found to be linked to the lower risk of prematurity-related complications. Further mechanistic studies will be required to reveal the role of circulating CD34+ cells in neonate.

Cite

CITATION STYLE

APA

Hamazaki, T., & Shintaku, H. (2018). CD34+ cell in cord blood and neonates. In Cell Therapy for Perinatal Brain Injury (pp. 77–82). Springer Singapore. https://doi.org/10.1007/978-981-10-1412-3_8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free